

Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice: Insights from 2021



Dr Elizabeth Smyth
Clinical Consultant
Gastrointestinal Oncology
Addenbrooke's Hospital
Cambridge, UK


Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by touchIME® to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by touchIME® of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME® activities*
- *touchIME® accept no responsibility for errors or omissions*

CheckMate 648: Study design




- Unresectable advanced, recurrent or metastatic ESCC
- ECOG PS 0 or 1
- No prior systemic treatment for advanced disease
- Measurable disease



Nivolumab + ipilimumab or nivolumab + chemotherapy vs chemotherapy as first-line treatment for advanced ESCC


CheckMate 648: Median overall survival (months)




CI, confidence interval; HR, hazard ratio; PD-L1, programmed death-ligand 1.

1. Chau I, et al. *J Clin Oncol*. 2021;39(Suppl. 18):LBA4001; 2. Chau I, et al. Oral presentation at ASCO, 4-8 June 2021, Chicago, IL, USA: LBA7.

CheckMate 648: Median progression-free survival (months)



CheckMate 648: Treatment-related adverse events (grade 3 or 4)*



- For all randomized patients and those with PD-L1 $\geq 1\%$:
 - Superior median OS with both IO combinations vs chemotherapy alone
 - Clinically meaningful PFS benefit with nivolumab + chemotherapy
- No new safety signals with either combined IO regimen

*Select treatment-related adverse events with potential immunologic aetiology that require frequent monitoring/intervention.

IO, immunotherapy.

1. Chau I, et al. *J Clin Oncol*. 2021;39(Suppl. 18):LBA4001; 2. Chau I, et al. Oral presentation at ASCO, 4-8 June 2021, Chicago, IL, USA: LBA7.

ORIENT-15: Study design



- Unresectable locally advanced or metastatic ESCC
- ECOG PS 0 or 1
- ≥18 years old
- At least one measurable lesion

n=332


Placebo Q3W, for a maximum of 24 months + chemo Q3W for a maximum of 6 cycles

n=327


Sintilimab Q3W, for a maximum of 24 months + chemo Q3W for a maximum of 6 cycles

Sintilimab + chemotherapy vs chemotherapy as first-line therapy in patients with advanced or metastatic ESCC

ORIENT-15: Key study endpoints



ORIENT-15: Treatment-related adverse events



TRAEs with ≥15% incidence

Anaemia	Alopecia
Decreased WBCs	Decreased appetite
Decreased neutrophils	Hypoaesthesia
Nausea	Decreased platelets
Vomiting	Decreased weight
Asthenia	Rash

- Superior median overall survival and durable responses with sintilimab + chemotherapy than chemotherapy alone regardless of PD-L1 expression
- No new safety signals with the IO combination

JUPITER-06: Study design



- Histologically or cytologically confirmed advanced or metastatic ESCC
- Treatment-naïve for metastatic disease
- ECOG PS 0 or 1
- Measurable disease

n=257


Placebo + chemo Q3W for up to 6 cycles followed by maintenance placebo Q3W

n=257

Toripalimab 240 mg + chemo Q3W for up to 6 cycles followed by maintenance 240 mg toripalimab Q3W


Randomized, double-blind, phase III study of toripalimab vs placebo in combination with first-line chemotherapy for treatment naïve advanced or metastatic ESCC

JUPITER-06: Median overall survival (months) – interim analysis



- PFS median 5.7 vs 5.5 months (HR, 0.58; 95% CI, 0.461–0.738; p<0.00001)

JUPITER-06: Treatment-related adverse events – interim analysis



- Superior OS and PFS with IO than chemo alone
- OS and PFS benefits were observed regardless of PD-L1 expression
- No new safety signals

ESCORT-1st: Study design



- Histologically or cytologically confirmed ESCC
- Treatment-naïve
- Advanced or metastatic disease
- ECOG PS 0 or 1
- Measurable disease

n=298


Placebo QW3 + chemo Q3W
+ chemo Q3W for ≤6 cycles

n=298


Camrelizumab 200 mg Q3W
+ chemo Q3W for ≤6 cycles

Randomized, double-blind, placebo-controlled, phase III trial
of camrelizumab + chemotherapy vs chemotherapy in
patients with untreated advanced or metastatic ESCC

ESCORT-1st: Key endpoints – interim analysis



ESCORT-1st: Treatment-related adverse events – interim analysis



TRAEs with ≥20% incidence

RCCEP

Alopecia

Anaemia

Decreased appetite

Decreased WBCs

Vomiting

Decreased neutrophils

Decreased platelets

Nausea

Decreased weight

Asthenia

Increased creatine

- Superior OS and PFS with IO than placebo + chemotherapy
- Manageable safety profile

RATIONALE 302: Study design



- Advanced or metastatic ESCC
- Progression during or after first-line systemic treatment
- ECOG PS 0 or 1

n=256


Investigator-chosen chemo

n=256


Tislelizumab 200 mg Q3W

Randomized, phase III study of second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC

RATIONALE 302: Key endpoints



RATIONALE 302: Treatment-emergent and -related adverse events



- Superior OS and more durable response with IO than chemotherapy alone
- OS benefit was observed regardless of PD-L1 expression
- No new safety signals

TEAE, treatment-emergent adverse event.

1. Shen L, et al. *J Clin Oncol*. 2021;39(Suppl. 15):4012; 2. Shen L, et al. Oral presentation at ASCO, 4-8 June 2021, Chicago, IL, USA: 4012.

CheckMate 577: Study design



- Stage II/III EC or GEJC
- Adenocarcinoma or squamous cell carcinoma
- Neoadjuvant chemoradiotherapy and surgical resection
- Residual pathologic disease
- ECOG PS 0 or 1

n=262


Placebo Q2W for 16 weeks
then Q4W

n=532


Nivolumab 240 mg Q2W for
16 weeks then 480 mg Q4W

Adjuvant nivolumab in resected esophageal or gastroesophageal
junction cancer following neoadjuvant chemoradiotherapy

CheckMate 577: Median disease-free survival (months)



CheckMate 577: Adverse and treatment-related adverse events













- Adjuvant IO was superior to placebo in patients following neoadjuvant chemoradiotherapy
- Acceptable safety profile

AE, adverse event.

1. Kelly RJ, et al. *J Clin Oncol*. 2021;39(Suppl. 15):4003; 2. Kelly RJ, et al. Oral presentation at ASCO, 4–8 June 2021, Chicago, IL, USA: 4003.

Summary and conclusions

Anti-PD-1 mAb	Outcome vs comparator*	Adjuvant	1L combo with chemo	2L mono
Nivo		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Sint			<input checked="" type="checkbox"/>	
			<input checked="" type="checkbox"/>	
Tori			<input checked="" type="checkbox"/>	
			<input checked="" type="checkbox"/>	
Cam			<input checked="" type="checkbox"/>	
			<input checked="" type="checkbox"/>	
Tis				<input checked="" type="checkbox"/>
				<input checked="" type="checkbox"/>

 Efficacy  Safety


*Comparator arms were placebo, chemo or placebo + chemo.
Combo, combination; mAb, monoclonal antibody; mono, monotherapy.

Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice: Insights from ASCO and ESMO GI 2022



Dr Elizabeth Smyth
Clinical Consultant
Gastrointestinal Oncology
Addenbrooke's Hospital
Cambridge, UK

New standards for care with checkpoint inhibitors: First line¹



New standards for care with checkpoint inhibitors: First line

	CheckMate 648 ¹		KEYNOTE 590 ²
PD-L1 expression	PD-L1 TPS ≥1%		PD-L1 CPS ≥10
Geography	Global Asia 70%		Global Asia ~50%
Treatment arm(s)	Nivo	Nivo + ipi	Pembro
Chemo arm(s)	Cisplatin + FP	None	Cisplatin + FP
Tumour type	ESCC		Adenocarcinoma 27% ESCC 73%
Primary endpoints	OS + PFS		OS + PFS

CheckMate 648 expanded analysis: Study design



Extended analysis included exploratory endpoints

- OS by baseline PD-L1 and PD-L1 CPS status
- PFS2*
- DOR
- Safety (onset and resolution of TRAEs with potential immunologic aetiology)

n=321

Nivo 240 mg Q2W +
chemo Q4W

n=325

Nivo 3 mg/kg Q2W +
ipi 1 mg/kg Q6W


n=324

Chemo Q4W

Nivo + ipi or nivo + chemo vs chemo as
first-line treatment for advanced ESCC

*PFS2 is defined as the time from randomization to objective tumour progression on next-line treatment or death from any cause.
Chemo, chemotherapy; CPS, combined positive score; DOR, duration of response; ESCC, esophageal squamous cell carcinoma; ipi, ipilimumab; nivo, nivolumab;
OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; Q2/4/6W, once every 2/4/6 weeks.
Chau I, et al. *J Clin Oncol*. 2022;40(Suppl. 16):4035.


CheckMate 648: Median PFS2* (months)¹



Favourable PFS2 observed with both nivo + chemo and nivo + ipi vs chemotherapy

*PFS2 is defined as the time from randomization to objective tumour progression on next-line treatment or death from any cause. Chemo, chemotherapy; CI, confidence interval; HR, hazard ratio; ipi, ipilimumab; nivo, nivolumab; PFS, progression-free survival.
1. Chau I, et al. *J Clin Oncol*. 2022;40(Suppl. 16):4035.

CheckMate 648: Median duration of response (months)



A larger proportion of responders had prolonged DOR (≥12 months) with nivo + chemo or nivo + ipi vs chemo alone

No new safety signals identified from initial analysis
TRAEs with potential immunologic aetiology resolved in most patients with appropriate management

RATIONALE 306: Study design^{1,2}



n=649

- Stage IV unresectable ESCC at first diagnosis, or locally advanced recurrent or metastatic ESCC
- 6-month treatment-free interval following prior definitive therapy
- No prior systemic treatment for unresectable advanced disease

1:1

n=326

Tis 200 mg Q3W +
Pt-doublet chemo


n=323

Pt-doublet chemo arms
comprised CIS-Pt or OX-Pt plus:
A 5-FU **B** CAP **C** PAC

PBO +
Pt-doublet chemo

Tis + chemo vs chemo as first-line treatment for advanced ESCC

RATIONALE 306: Median survival outcomes (all randomized)



Risk of death: HR 0.66
(95% CI 0.54–0.80; $p < 0.0001$)


34% reduced risk of death

Risk of progression: HR 0.62
(95% CI 0.52–0.75; $p < 0.0001$)

38% reduced risk of progression


First-line tislelizumab + chemo achieved a statistically significant mOS benefit compared with placebo + chemo

RATIONALE 306: Median overall survival by tumour PD-L1 status



Risk of death: HR 0.62
(95% CI 0.44–0.86; p=0.002)

38% reduced risk of death



Risk of death: HR 0.72
(95% CI 0.55–0.94)

28% reduced risk of progression

Tislelizumab + chemo achieved significant survival benefit regardless of tumour PD-L1 status


RATIONALE 306: Safety outcomes

Most common TRAEs, %
(incidence $\geq 20\%$)

	Tislelizumab + chemo	Placebo + chemo
Anaemia	68	61
Neutropenia	78	80
Lymphopenia	55	65
Decreased appetite	39	38
Nausea	37	42
PNS	26	21
% Patients with ≥ 1 immune-mediated AE	22	6

Frequency of common TRAEs reported with tislelizumab + chemo were comparable with placebo + chemo

New standards for care with checkpoint inhibitors: Second line¹



Real-world study of anti-PD-1 second-line therapy: Study design




- Advanced or metastatic ESCC
- Initiated an anti-PD-1 second-line therapy between 1 January 2011 and 28 February 2021

N=60

- Patient characteristics
- Descriptive treatment patterns
- Duration of therapy
- Overall survival


Electronic health record-derived database analysis

Real-world study of anti-PD-1 second-line therapy: Results



Consistent with trial findings, real-world data further validate that anti-PD-1 therapies as second-line treatment may be associated with improved survival in comparison with non-anti-PD-1 therapies

RATIONALE 302 health-related quality of life: Study design^{1,2}



RATIONALE 302: health-related quality of life endpoints

		Tislelizumab (N=256)		ICC (N=256)	
		Cycle 4	Cycle 6	Cycle 4	Cycle 6
QLQ-C30	GHS/QoL	0.0 (-2.5, 2.4)	-0.8 (-3.5, 2.0)	-5.8 (-8.8, -2.8)	-8.9 (-12.8, -4.9)
	Physical functioning	-4.0 (-6.3, -1.8)	-4.6 (-7.1, -2.1)	-6.6 (-9.3, -4.0)	-8.9 (-12.1, -5.6)
	Fatigue	3.5 (0.4, 6.6)	1.0 (-2.1, 4.2)	11.3 (7.5, 15.1)	6.4 (2.0, 10.9)
QLQ-OES18	Dysphagia	2.7 (-1.7, 7.1)	1.6 (-3.5, 6.6)	7.7 (2.2, 13.2)	1.9 (-5.5, 9.2)
	Reflux	-2.3 (-4.6, -0.1)	-1.8 (-4.7, 1.2)	1.8 (-1.1, 4.7)	-1.1 (-5.4, 3.2)
	Eating	0.0 (-2.8, 2.8)	-0.5 (-3.6, 2.6)	2.7 (-0.8, 6.2)	4.7 (0.3, 9.1)
	Pain	-1.6 (-3.4, 0.2)	-1.4 (-3.9, 1.0)	-1.1 (-3.6, 1.3)	0.2 (-3.6, 4.1)

Summary and conclusions

First-line treatment of ESCC

Tislelizumab has demonstrated potential to join nivolumab and pembrolizumab (in combination with chemotherapy) as a new standard of care

Second-line treatment of ESCC


Real-world and health-related QoL findings support anti-PD-1 use

Updated ESMO Clinical Practice Guideline for esophageal squamous cell carcinoma and insights from 2022 on potential future treatment options



Dr Elizabeth Smyth
Clinical Consultant
Gastrointestinal Oncology
Addenbrooke's Hospital
Cambridge, UK

Treatment algorithm for advanced ESCC



First-line chemotherapy for ESCC

Advanced ESCC¹

PD-L1 negative
or low


Platinum +
fluoropyrimidine

JCOG9407: Phase II study of
cisplatin + 5-FU²

Phase II study of cisplatin
+ 5-FU vs cisplatin alone³

Overall
response rate
33.3%
(95% CI 18.6–54.6)

1-year
survival rate
33.3%
(95% CI 19.1–47.6)



First-line immune checkpoint inhibitors ± chemotherapy for ESCC


Advanced ESCC¹

PD-L1 CPS ≥ 10

Pembrolizumab
+ ChT

KEYNOTE-590: Phase III trial of pembrolizumab + chemotherapy vs placebo + chemotherapy^{2*}

KEYNOTE-590: Post hoc analysis in patients with PD-L1 CPS < 10 [†]



*73% of study patients with ESCC; ~50% Asian. †32-34% of study patients with ESCC.

CI, confidence interval; CPS, combined positive score; ChT, chemotherapy; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; PD-L1, programmed death-ligand 1; Pembro, pembrolizumab.

1. Obermannová R, et al. *Ann Oncol*. 2022;33:992-1004; 2. Sun J-M, et al. *Lancet*. 2021;398:759-71.


First-line immune checkpoint inhibitors ± chemotherapy for ESCC

Advanced ESCC¹


PD-L1 TPS ≥1%

Nivolumab + ChT
OR
Nivolumab + ipilimumab

CheckMate 648: Phase III study of nivolumab + ipilimumab or nivolumab + chemotherapy vs chemotherapy^{2,3}



Median progression-free survival 2*



Median duration of response

*PFS2 is defined as the time from randomization to objective tumour progression on next-line treatment or death from any cause.


CI, confidence interval; ChT, chemotherapy; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; Ipi, ipilimumab; Nivo, nivolumab; PD-L1, programmed death-ligand 1; TPS, tumour positivity score.

1. Obermannová R, et al. *Ann Oncol.* 2022;33:992-1004; 2. Chau I, et al. *J Clin Oncol.* 2022;40(Suppl. 16):4035; 3. Chau I, et al. Presented at ASCO, Chicago, IL, USA. 3-7 June 2022: #4035.

Second and subsequent lines of treatment for ESCC¹




ATTRACTION-3: Phase III study of nivolumab vs chemotherapy following refractory disease or intolerance to previous chemotherapy²




Median overall survival

Second and subsequent lines of treatment for ESCC



Second and subsequent lines of treatment for ESCC



*94% of patients with ESCC; [†]Response Evaluation Criteria in Solid Tumors criteria.; [‡]50% of patients with ESCC.

CI, confidence interval; ESCC, esophageal squamous cell carcinoma; mo, months; mOS, median overall survival; ORR, overall response rate.

1. Obermannová R, et al. *Ann Oncol.* 2022;33:992–1004; 2. Kato K, et al. *Cancer Chemother Pharmacol.* 2011;67:1265–72; 3. Muro K, et al. *Ann Oncol.* 2004;15:955–9;

4. Burkart C, et al. *Anticancer Res.* 2007;27:2845–8.

Summary: 2022 ESMO Clinical Practice Guideline

First-line treatment for advanced ESCC

- First-line chemotherapy with a platinum and fluoropyrimidine is recommended as a standard treatment for advanced untreated ESCC
 - Dose-reduced oxaliplatin + capecitabine is an alternative option for patients who are unsuitable for full-dose chemotherapy
- Pembrolizumab + chemotherapy is recommended for advanced, untreated ESCC
 - The greatest benefit is seen in patients with a PD-L1 CPS ≥ 10
- Nivolumab + chemotherapy is recommended in patients with tumours expressing PD-L1 with a TPS $\geq 1\%$

Summary: 2022 ESMO Clinical Practice Guideline

Second and subsequent lines of treatment for advanced ESCC¹


- Nivolumab is recommended for ESCC previously treated with platinum + fluoropyrimidine chemotherapy
- Where approved, pembrolizumab may be an option for patients with previously treated ESCC who have not received first-line treatment with immune checkpoint inhibitors and have a PD-L1 CPS ≥ 10
- Chemotherapy with a taxane or irinotecan can be considered in fit patients who have been previously treated with platinum + fluoropyrimidine and/or nivolumab or pembrolizumab

Chemotherapy plus nivolumab should be the standard of care for most patients²

- Chemotherapy may be avoided in selected patients, but careful counselling is needed to elaborate the risk of lower response and early progression²


Potential change to standard of care in ESCC: First-line

RATIONALE-306: First-line tislelizumab + chemotherapy achieved a statistically significant OS and PFS benefit compared with placebo + chemotherapy¹




Potential change to standard of care in ESCC: First-line

ESCORT-1st: Camrelizumab + chemotherapy provided superior OS and PFS vs placebo + chemotherapy^{1,2}



Potential change standard of care in ESCC: Second-line

RATIONALE-302: Tislelizumab significantly improved OS compared with chemotherapy as second-line therapy in patients with advanced or metastatic ESCC



Summary: New and emerging treatment options

First-line treatment for advanced ESCC

- **RATIONALE-306:** First-line tislelizumab + chemotherapy achieved a statistically significant mOS benefit compared with placebo + chemotherapy¹
- **ESCORT-1st:** Camrelizumab + chemotherapy provided superior OS and PFS vs placebo + chemotherapy²

Second and subsequent lines of treatment for advanced ESCC

- **RATIONALE-302:** Tislelizumab significantly improved OS compared with chemotherapy as second-line therapy in patients with advanced or metastatic ESCC³